re maybe11 Jan 2019 17:34
I guess nobody outside the US wants access? What about MRSA etc HABP and the fact that we have a protected revenue stream for each application? I have said it before there seems to be no problem is valuing canabis stocks for esoteric medical conditions. The fact is nobody has a handle of how many patients die every year all over the world from hospital acquired infections and surgeons are genuinely concerned about the outcome of surgical procedures as a result. We alll know we have a new type of antibiotic here, not some niche product. I have seen biotechs raped time and time again by the big boys such as Teva and Biogen. Fingers crossed our BoD is clued up enough which is more than can be said for the market advisors they have paid over the last few years.